NO920127L - Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr - Google Patents

Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr

Info

Publication number
NO920127L
NO920127L NO92920127A NO920127A NO920127L NO 920127 L NO920127 L NO 920127L NO 92920127 A NO92920127 A NO 92920127A NO 920127 A NO920127 A NO 920127A NO 920127 L NO920127 L NO 920127L
Authority
NO
Norway
Prior art keywords
uveoretinitis
mammals
treatment
autoimmun
prevention
Prior art date
Application number
NO92920127A
Other languages
English (en)
Norwegian (no)
Other versions
NO920127D0 (no
Inventor
Howard L Weiner
David A Hafler
Robert B Nussenblatt
Alan G Palestine
Original Assignee
Autoimmune Inc
Brigham & Womens Hospital
Nat Inst Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc, Brigham & Womens Hospital, Nat Inst Health filed Critical Autoimmune Inc
Publication of NO920127D0 publication Critical patent/NO920127D0/no
Publication of NO920127L publication Critical patent/NO920127L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Rehabilitation Therapy (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Emergency Protection Circuit Devices (AREA)
NO92920127A 1989-07-14 1992-01-09 Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr NO920127L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37977889A 1989-07-14 1989-07-14
US55163290A 1990-07-10 1990-07-10
PCT/US1990/003989 WO1991001333A1 (en) 1989-07-14 1990-07-16 Methods of treating or preventing autoimmune uveoretinitis in mammals

Publications (2)

Publication Number Publication Date
NO920127D0 NO920127D0 (no) 1992-01-09
NO920127L true NO920127L (no) 1992-01-09

Family

ID=27008768

Family Applications (1)

Application Number Title Priority Date Filing Date
NO92920127A NO920127L (no) 1989-07-14 1992-01-09 Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr

Country Status (15)

Country Link
US (1) US5961977A (da)
EP (1) EP0482089B1 (da)
JP (1) JP2607751B2 (da)
KR (1) KR0159046B1 (da)
AT (1) ATE158950T1 (da)
AU (1) AU670024B2 (da)
BR (1) BR9007527A (da)
CA (1) CA2063416C (da)
DE (1) DE69031563T2 (da)
DK (1) DK0482089T3 (da)
ES (1) ES2109234T3 (da)
FI (1) FI920139A0 (da)
HU (1) HUT63182A (da)
NO (1) NO920127L (da)
WO (1) WO1991001333A1 (da)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI920139A0 (fi) * 1989-07-14 1992-01-13 Autoimmune Inc Foerfaranden foer behandling och foerfindrande av autoimmun uveoretinitis hos daeggdjur.
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
US6812205B2 (en) 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
WO2001089557A2 (en) 2000-05-24 2001-11-29 The United States Of America, As Represented By Secretary Of The Department Of Health & Human Services Methods for preventing strokes by inducing tolerance to e-selectin
US20050220803A1 (en) * 2002-03-26 2005-10-06 Yeda Research And Development Co. Ltd. Use of an organ-specific self-pathogen for treatment of a non-autoimmune disease of said organ
CN100582085C (zh) 2002-10-10 2010-01-20 耶达研究及发展有限公司 脂肪醇的碱性酯及它们作为抗炎药或免疫调节剂的用途
EP1874334A4 (en) * 2005-04-15 2011-03-30 Vascular Biogenics Ltd COMPOSITIONS WITH BETA 2-GLYCOPROTEIN I-PEPTIDES FOR THE PREVENTION AND / OR TREATMENT OF VASCULAR DISEASES
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
HUE049261T2 (hu) 2014-07-15 2020-09-28 Yissum Research And Development Company Of The Hebrew Univ Of Jerusalem Ltd CD44 izolált polipeptidek és alkalmazásaik
JP7108823B2 (ja) 2016-12-19 2022-07-29 パナソニックＩｐマネジメント株式会社 取付装置、電子機器、取付装置の固定方法、およびシート
WO2023091887A1 (en) 2021-11-16 2023-05-25 Genentech, Inc. Methods and compositions for treating systemic lupus erythematosus (sle) with mosunetuzumab

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2512796B2 (ja) * 1987-06-24 1996-07-03 オートイミュン・インコーポレイテッド 自己抗原の経口投与による自己免疫疾患の治療法
FI920139A0 (fi) * 1989-07-14 1992-01-13 Autoimmune Inc Foerfaranden foer behandling och foerfindrande av autoimmun uveoretinitis hos daeggdjur.
DK0506785T3 (da) * 1989-12-20 2000-07-24 Autoimmune Inc Forbedret behandling af autoimmune sygdomme ved aerosol-administration af autoantigener

Also Published As

Publication number Publication date
CA2063416C (en) 2000-05-30
CA2063416A1 (en) 1991-01-15
AU670024B2 (en) 1996-07-04
NO920127D0 (no) 1992-01-09
DE69031563D1 (de) 1997-11-13
HU9200107D0 (en) 1992-04-28
WO1991001333A1 (en) 1991-02-07
DE69031563T2 (de) 1998-02-12
EP0482089A4 (en) 1993-02-17
DK0482089T3 (da) 1998-05-25
US5961977A (en) 1999-10-05
AU6058390A (en) 1991-02-22
ATE158950T1 (de) 1997-10-15
FI920139A7 (fi) 1992-01-13
EP0482089A1 (en) 1992-04-29
HUT63182A (en) 1993-07-28
KR0159046B1 (ko) 1998-11-16
FI920139A0 (fi) 1992-01-13
ES2109234T3 (es) 1998-01-16
EP0482089B1 (en) 1997-10-08
BR9007527A (pt) 1992-06-23
JPH05501866A (ja) 1993-04-08
JP2607751B2 (ja) 1997-05-07

Similar Documents

Publication Publication Date Title
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
IL99754A0 (en) Pharmaceutical composition for treatment of autoimmune diseases containing an autoantigen or a fragment or analogue thereof
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
NO920127D0 (no) Fremgangsmaate for behandling eller forhindring av autoimmun uveoretinitis i pattedyr
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
ATE130762T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen.
ES535860A0 (es) Procedimiento para la obtencion de un agente para la aplicacion transdermal de sustancias activas medicamentosas
BR9710452A (pt) Anïïlogos de exendina processos para sua prepara-Æo e medicamentos contendo os mesmos
BR9814473A (pt) Imunógenos anti-retrovirais, preparação e uso
DK183389A (da) Fremgangsmaade til fremstilling af en administrerings- og/eller doseringsform for medicinsk aktive materialer
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
KR950703353A (ko) 인슐린-의존적 진성 당뇨병을 예방 또는 치료하기 위한 인터루킨-10의 용도(Use of IL-10 to prevent or treat insulin-dependent diabetes mellitus)
DE69111974D1 (de) Verwendung von Lithium zur Behandlung oder Prophylaxe von Molluscum contagiusum.
UA7180C2 (uk) Препарат для лікування та профілактики атерогенних дисліпопротеїнемій та синдрому гіперкоагуляції

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application